TFF Pharma Inks Research Pact With US Army For Dry Powder Medical Countermeasures

TFF Pharmaceuticals Inc TFFP has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for defensive research into countermeasures against biological warfare.

  • Under the terms of the CRADA, TFF Pharma and USAMRIID will evaluate the immune response of a dry powder recombinant Vesicular Stomatitis Virus Severe Acute Respiratory Syndrome Coronavirus-2 Glycoprotein (TFFD-rVSV-SARS2-GP) vaccine formulated using TFF's Thin Film Freezing technology. 
  • USAMRIID will assess the immunogenicity and protective efficacy of inhaled dry powder formulation against SARS-CoV-2 induced in an animal model compared to the intramuscular administration.
  • Related: TFF Pharma's Inhaled Niclosamide Shows Potent Activity Against Omicron Variant.
  • Earlier in 2021, under the existing CRADA, TFF Pharmaceuticals announced positive preclinical data showing the two Thin Film Freezing-formulated biodefense countermeasures maintained efficacy in an in vitro viral neutralization assay. 
  • TFF Pharmaceuticals' Thin Film Freezing (TFF) platform is designed to improve the solubility and absorption of poorly water-soluble drugs. It is particularly suited to generate dry powder particles with properties targeted for inhalation delivery.
  • Price Action: TFFP shares are up 9.32% at $6.57 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!